PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: BioNet-Asia Co., Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BioNet-Asia to License Recombinant Pertussis Strain - BioNet-Asia Co., Ltd, announced the signature with a China-based company of a binding letter of intent to license a Bordetella pertussis strain, genetically modified to express antigens - BioNet-Asia.com
BioNet-Asia to License Recombinant Pertussis Strain

 

NewswireToday - /newswire/ - Bangkok, Thailand, 2012/01/13 - BioNet-Asia Co., Ltd, announced the signature with a China-based company of a binding letter of intent to license a Bordetella pertussis strain, genetically modified to express antigens - BioNet-Asia.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BioNet-Asia Co., Ltd, a vaccine-focused biotech company based in Thailand has announced today the signature with a China-based company of a binding letter of intent to license a Bordetella pertussis strain, genetically modified to express antigens that can be used in the development of acellular pertussis-based vaccines.

Acellular Pertussis Vaccines are now routinely and successfully used to prevent whooping cough disease, in Western Europe, North America, Japan and Korea but not in the emerging countries because of the high cost.

The advantages of the recombinant pertussis strain producing very high yields of inactivated pertussis toxins enable the production of a recombinant Acellular Pertussis Vaccine to be affordable in China and other developing countries.

Mr Vitoon Vonghangool, Managing Director of BioNet-Asia said “This is an important milestone because it is the outcome of years of research and development in Thailand.
Our company has been heavily affected by the floods in October 2011 and it was important to find a partner interested in our recombinant pertussis strain. We expect to receive double-digit million dollars over a period of 10 years followed by royalties. Upfront payments are expected within this year and will be used to reconstruct our facilities.”
Dr Pham Hong Thai, Managing Director of BioNet-Asia concluded that “The agreement will be signed within a couple of months and we are also in discussion with some vaccine manufacturers for collaboration on recombinant acellular pertussis based vaccines.”

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: BioNet-Asia Co., Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BioNet-Asia to License Recombinant Pertussis Strain

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: BioNet-Asia.com 
+662 361 8110 info[.]bionet-asia.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any BioNet-Asia Co., Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From BioNet-Asia Co., Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit MagLar, Inc.

Visit  Explorers Vacation Club





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)